This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
Bone Marrow Transplantation Open Access 11 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schonland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30:2047–54. https://doi.org/10.1038/leu.2016.101
Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121:5055–63. https://doi.org/10.1182/blood-2012-11-469452
Rasche L, Rollig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features. Biol Blood Marrow Transplant. 2016;22:1988–96. https://doi.org/10.1016/j.bbmt.2016.08.024
Hatsuse M, Taniguchi-Yoshihara K, Yagyu S, Fuchida S, Okano A, Murakami S, et al. Successful treatment with pseudo-autologous bloodstem cell transplantation for an adolescent-onset multiple myeloma whorelapsed after allogenic bone marrow transplantation. Rinsho Ketsueki. 2015;56:428–431. https://doi.org/10.11406/rinketsu.56.428
Palfreyman E, Song K, Nantel S. Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:1138 https://doi.org/10.1038/bmt.2013.12
Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126:921–2. https://doi.org/10.1182/blood-2015-05-647636
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20:382–6. https://doi.org/10.1016/j.bbmt.2013.11.034
Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2016;22:258–67. https://doi.org/10.1016/j.bbmt.2015.08.025
Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19:398–404. https://doi.org/10.1016/j.bbmt.2012.10.008
Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103:4362–4. https://doi.org/10.1182/blood-2003-11-3862
Kroger N, Kruger W, Renges H, Zabelina T, Stute N, Jung R, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol. 2001;112:421–3.
Kroger N, Zabelina T, Klyuchnikov E, Kropff M, Pfluger KH, Burchert A, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48:403–7. https://doi.org/10.1038/bmt.2012.142
Author information
Authors and Affiliations
Contributions
NK designed the study and wrote the paper. PN analysed data, interpreted results, and wrote the paper. MG prepared CD34 selection. EK, UvP, MG, MC, FA, and CW analysed data, interpreted results, and approved the final version of the paper.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Novak, P., Klyuchnikov, E., von Pein, UM. et al. Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. Bone Marrow Transplant 55, 1817–1820 (2020). https://doi.org/10.1038/s41409-020-0912-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0912-7
This article is cited by
-
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
Bone Marrow Transplantation (2021)